Globeflex Capital L P Purchases Shares of 28,363 Neurocrine Biosciences, Inc. $NBIX

Globeflex Capital L P purchased a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 28,363 shares of the company’s stock, valued at approximately $4,780,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. DJE Kapital AG bought a new position in Neurocrine Biosciences during the fourth quarter valued at about $28,000. Geneos Wealth Management Inc. raised its position in Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after acquiring an additional 135 shares in the last quarter. Meeder Asset Management Inc. raised its position in Neurocrine Biosciences by 651.6% in the fourth quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock worth $33,000 after acquiring an additional 202 shares in the last quarter. Basecamp Wealth Advisors LLC lifted its holdings in Neurocrine Biosciences by 582.9% in the 1st quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock valued at $31,000 after acquiring an additional 204 shares during the last quarter. Finally, Cassaday & Co Wealth Management LLC bought a new position in shares of Neurocrine Biosciences during the 1st quarter valued at about $33,000. Institutional investors own 92.59% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on NBIX. BMO Capital Markets lifted their price objective on shares of Neurocrine Biosciences from $144.00 to $170.00 and gave the stock a “market perform” rating in a research note on Monday, July 13th. Truist Financial raised their target price on shares of Neurocrine Biosciences from $200.00 to $213.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Weiss Ratings lowered shares of Neurocrine Biosciences from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, August 11th. Wedbush upped their price target on Neurocrine Biosciences from $185.00 to $194.00 and gave the company an “outperform” rating in a report on Monday, August 3rd. Finally, Cantor Fitzgerald increased their price objective on Neurocrine Biosciences from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $200.86.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Jude Onyia sold 11,000 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $160.25, for a total transaction of $1,762,750.00. Following the sale, the insider directly owned 25,846 shares of the company’s stock, valued at $4,141,821.50. The trade was a 29.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Ingrid Delaet sold 8,433 shares of the stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $178.72, for a total value of $1,507,145.76. Following the completion of the sale, the insider owned 16,225 shares of the company’s stock, valued at $2,899,732. The trade was a 34.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 131,524 shares of company stock worth $21,668,924. 4.60% of the stock is currently owned by insiders.

Neurocrine Biosciences Stock Performance

NBIX stock opened at $152.57 on Monday. Neurocrine Biosciences, Inc. has a one year low of $122.14 and a one year high of $186.12. The firm has a 50-day moving average of $167.14 and a two-hundred day moving average of $148.96. The firm has a market capitalization of $15.51 billion, a PE ratio of 22.37, a P/E/G ratio of 0.71 and a beta of 0.39.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Friday, July 31st. The company reported $2.85 earnings per share for the quarter, topping the consensus estimate of $1.65 by $1.20. Neurocrine Biosciences had a net margin of 20.91% and a return on equity of 22.43%. The business had revenue of $959.00 million for the quarter, compared to the consensus estimate of $891.16 million. During the same period last year, the firm posted $1.65 earnings per share. The firm’s quarterly revenue was up 39.5% compared to the same quarter last year. On average, equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 7.25 earnings per share for the current year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.